IgM B. burgdorferi AG

Sample type: Serum
Optimal result: 0 – 0.81 index

The IgM B. burgdorferi Antigen (AG) test measures early antibodies against a broad set of Borrelia burgdorferi proteins, making it a sensitive marker for detecting early Lyme disease. IgM antibodies typically appear within 1–2 weeks after a tick bite and peak in the first month, so a positive result may indicate a recent or active infection. However, IgM alone is not diagnostic: results can persist after treatment or arise from cross-reactions with other infections or autoimmune conditions. Therefore, this marker is most valuable when interpreted with symptoms, exposure history, IgG results, and confirmatory tests. As part of a comprehensive Lyme serology panel, the IgM AG test supports early recognition and management of Lyme disease, helping to prevent progression to later complications affecting joints, the nervous system, or the heart.

An equivocal result means your IgM antibody level is right at the borderline — not clearly negative, but not strongly positive either. This does not confirm Lyme disease. Sometimes this happens if the test is done very soon after a tick bite, before antibodies fully develop, or because of background signals in the immune system. Your doctor may suggest repeating the test after a few weeks, checking for other antibodies, and reviewing your symptoms and history before making any diagnosis.

IgM B. burgdorferi Antigen (AG) Test: Early Antibody Marker for Lyme Disease

Overview

The IgM B. burgdorferi Antigen (AG) test detects early-stage antibodies against Borrelia burgdorferi, the spirochete bacterium responsible for Lyme disease. Unlike subspecies- or protein-specific assays, this test measures IgM antibodies directed against a broader set of Borrelia antigens, improving sensitivity and making it a valuable tool in the early detection of Lyme borreliosis.


The Role of IgM Antibodies

IgM is the first class of antibodies produced by the immune system during infection. In Lyme disease:

  • IgM typically appears 1–2 weeks after a tick bite

  • Peaks during the first month of infection

  • Declines as IgG antibodies become more dominant

Measuring IgM against Borrelia antigens provides insight into a recent or active immune response, making it particularly useful in identifying early-stage infection.


Clinical Significance

A positive IgM response against B. burgdorferi antigens suggests a possible recent infection. This is especially relevant for patients with:

  • Early Lyme symptoms such as erythema migrans (bull’s-eye rash), fever, fatigue, headache, or muscle aches

  • Neurological manifestations including cranial neuritis, meningitis, or cognitive changes

  • Musculoskeletal involvement such as migratory joint pain or early Lyme arthritis

Because IgM reflects the early immune response, this marker can support recognition of Lyme disease before complications such as arthritis, carditis, or neuroborreliosis develop.


Limitations and Considerations

  • False positives may occur due to cross-reactivity with other infections or autoimmune conditions

  • Isolated IgM positivity without subsequent IgG development, particularly beyond 6–8 weeks of symptoms, may not indicate active infection

  • Persistent IgM antibodies can be detected in some individuals even after treatment, making clinical context essential

  • Additional testing with subspecies markers (B. afzelii, B. garinii) or antibodies to Outer Surface Proteins (OspA, OspC, OspE) can improve diagnostic accuracy when interpreted alongside IgM AG results


Broader Context in Lyme Testing

Traditional Lyme serology, such as ELISA and Western Blot, measures antibodies to mixtures of Borrelia proteins. While sensitive, these methods may lack specificity. Newer multi-antigen ELISA and next-generation immunoserology approaches combine cultured Borrelia antigens with in vivo–expressed proteins, allowing for more precise differentiation between Lyme disease and other conditions. The IgM B. burgdorferi AG test remains a foundational early marker within this broader testing strategy.


Summary

The IgM B. burgdorferi Antigen (AG) test captures the body’s early antibody response to Lyme disease. A positive result may support the diagnosis of a recent or ongoing infection, but it should never be interpreted in isolation. Results are most informative when combined with clinical history, symptom timing, IgG antibodies, and confirmatory testing. As part of a comprehensive serologic panel, this marker plays a key role in the early identification and management of Lyme disease, helping to prevent progression to later-stage complications.

IgM B. burgdorferi AG
Healthmatters dashboard showing biomarker trend graph

Every lab result you’ve ever had, charted and explained.

Healthmatters is a tracker for your lab results. Upload a report from any lab, any country — every marker charted and explained.

Start with my report →
Beyond IgM B. burgdorferi AG — 10,000+ markers explained
One IgM B. burgdorferi AG result tells you where you are. Your history tells you where you’re heading. Upload your past lab reports and see this marker — and every marker on them —every marker charted against your own lab’s ranges.
Start with this report →
Healthmatters timeline preview showing biomarker trends over time
Clinical Sources & References

All our content is backed by peer-reviewed studies, academic research, and trusted medical sources. We’re committed to accuracy and transparency — see our editorial policy for details.

Article Review Log
Written by Healthmatters Editorial Team
Healthmatters Lifetime Plan

Pay $250. Track your health forever

One payment. No renewals. Yours for life.

10,000+ biomarkers explained · trends over time

See other plans →
Secure checkout via Stripe · GDPR & HIPAA
We accept results from any lab
LabCorp Quest Diagnostics Genova Diagnostics DUTCH Test Doctor's Data Vibrant America ZRT Laboratory Cyrex Labs + any other lab

What members are saying

★★★★★ 10,000+ happy members
★★★★★

"Watching my numbers move over the years — instead of forgetting last time's results — completely changed how I manage my health."

Daniel
Member since 2022
★★★★★

"Living across several countries made keeping my lab results organized a real challenge. Healthmatters brought my results from the USA, Spain, and Germany together — 20 years of history, with long-term trends instead of scattered reports."

Ben
Member since 2021 · tracks across countries
★★★★★

"Standard lab ranges are too wide for how I practice — 'normal' isn't optimal. I set my own bands, so a client sees yellow before a marker goes officially out of range. That's the conversation I want to be having."

Dr. Alexandra
Functional medicine · 6 yrs on Pro